Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388882 · ClinicalTrials.gov registry record · Phase 4
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT00388882 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 327 participants, below the 1,040-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00388882, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.
Conditions Studied
Interventions
- DRUG tiotropium
- DRUG ipratropium bromide / albuterol
Study Locations (20)
Other
- 205.346.510 - Bs As
- 205.346.502 - Buenos Aires
- 205.346.503 - Buenos Aires
- 205.346.508 - Buenos Airess
- 205.346.505 - Mendoza
- 205.346.509 - Rosario, Santa Fe
- 205.346.511 - Rosario, Santa Fé
- 205.346.504 Instituto de Patologías Respiratorias - San Miguel de Tucumán
- 205.346.401 Boehringer Ingelheim Investigational Site - Alytus
- 205.346.404 Boehringer Ingelheim Investigational Site - Kaunas
California
- 205.346.104 Boehringer Ingelheim Investigational Site - Lakewood
- 205.346.108 Boehringer Ingelheim Investigational Site - Sepulveda
- 205.346.101 Boehringer Ingelheim Investigational Site - Torrance
South Carolina
- 205.346.105 Boehringer Ingelheim Investigational Site - Charleston
- 205.346.103 Boehringer Ingelheim Investigational Site - Spartanburg
Arizona
- 205.346.107 Boehringer Ingelheim Investigational Site - Phoenix
Colorado
- 205.346.106 Boehringer Ingelheim Investigational Site - Wheat Ridge
Idaho
- 205.346.102 Boehringer Ingelheim Investigational Site - Coeur d'Alene
Louisiana
- 205.346.109 Boehringer Ingelheim Investigational Site - Shreveport
Pennsylvania
- 205.346.110 Boehringer Ingelheim Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2006-10-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388882
The ClinicalTrials.gov registry entry for NCT00388882 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,040-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (69% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which tiotropium is the first listed.
NCT00388882 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00388882 about?
NCT00388882 is a clinical study titled "Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.". The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.
What is the current status of trial NCT00388882?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 327 participants. The study started on 2006-10-04.
What conditions does trial NCT00388882 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00388882?
The interventions under investigation include: tiotropium (DRUG), ipratropium bromide / albuterol (DRUG).
Who is sponsoring clinical trial NCT00388882?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00388882 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
COMPLETED · Phase 4
-
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
COMPLETED · Phase 4
-
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
COMPLETED · Phase 4
-
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
COMPLETED · Phase 4
-
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
COMPLETED · Phase 4
-
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.